{"id":860263,"date":"2025-06-12T16:54:41","date_gmt":"2025-06-12T20:54:41","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/rckt-investor-alert-rocket-pharmaceuticals-inc-investors-with-substantial-losses-have-opportunity-to-lead-the-rocket-pharmaceuticals-class-action-lawsuit\/"},"modified":"2025-06-12T16:54:41","modified_gmt":"2025-06-12T20:54:41","slug":"rckt-investor-alert-rocket-pharmaceuticals-inc-investors-with-substantial-losses-have-opportunity-to-lead-the-rocket-pharmaceuticals-class-action-lawsuit","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/rckt-investor-alert-rocket-pharmaceuticals-inc-investors-with-substantial-losses-have-opportunity-to-lead-the-rocket-pharmaceuticals-class-action-lawsuit\/","title":{"rendered":"RCKT INVESTOR ALERT: Rocket Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead the Rocket Pharmaceuticals Class Action Lawsuit"},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n
\n SAN DIEGO<\/span>
\n <\/span>, June 12, 2025<\/span><\/span> \/PRNewswire\/ —Robbins Geller Rudman<\/span> & Dowd LLP<\/a><\/b> announces that purchasers or acquirers of Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) securities between February 27, 2025<\/span> and May 26, 2025<\/span>, inclusive (the “Class Period”), have until August 11, 2025<\/span> to seek appointment as lead plaintiff of the Rocket Pharmaceuticals <\/i>class action lawsuit. Captioned\u00a0Ho v. Rocket Pharmaceuticals, Inc.<\/i>, No. 25-cv-10049 (D.N.J.), the Rocket Pharmaceuticals <\/i>class action lawsuit charges Rocket Pharmaceuticals and one of Rocket Pharmaceuticals’ top executives with violations of the Securities Exchange Act of 1934.<\/p>\n

\n

\n
\n \"Robbins
\n <\/a>\n <\/p>\n<\/p><\/div>\n

\n If you suffered substantial losses and wish to serve as lead plaintiff of the Rocket Pharmaceuticals <\/i>class action lawsuit, please provide your information here:<\/b>\n <\/p>\n

\n
\n https:\/\/www.rgrdlaw.com\/cases-rocket-pharmaceuticals-inc-class-action-lawsuit-rckt.html<\/a>
\n <\/b>\n <\/p>\n

\n You can also contact attorneys J.C. Sanchez<\/a> or Jennifer N. Caringal<\/span><\/a> of Robbins Geller by calling 800\/449-4900 or via e-mail at info@rgrdlaw.com<\/a>.<\/b>\n <\/p>\n

\n CASE ALLEGATIONS<\/b>: Rocket Pharmaceuticals operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases.<\/p>\n

The Rocket Pharmaceuticals <\/i>class action lawsuit alleges<\/span> that defendants provided investors with material information concerning Rocket Pharmaceuticals’ Phase 2 pivotal trial of RP-A501 for the treatment of Danon disease while, at the same time, disseminating materially false and misleading statements and\/or concealing material adverse facts concerning the true state of RP-A501’s safety and clinical trial protocol; notably, that Rocket Pharmaceuticals knew Serious Adverse Events, including death of participants enrolled in the study, were a risk. In particular, Rocket Pharmaceuticals amended the trial’s protocol to introduce a novel\u00a0immunomodulatory agent to the pretreatment regimen without providing this critical update to shareholders, according to the complaint.<\/p>\n

The Rocket Pharmaceuticals<\/i> class action lawsuit further alleges<\/span> that on May 27, 2025<\/span>, Rocket Pharmaceuticals announced that the U.S. Food and Drug Administration placed a clinical hold on the RP-A501 Phase 2 pivotal study after at least one patient suffered a Serious Adverse Event, ultimately, death, while enrolled in the study following a substantive amendment to the protocol that Rocket Pharmaceuticals failed to disclose to investors at the time management made the revision. On this news, the price of Rocket Pharmaceuticals stock fell, according to the complaint.<\/p>\n

\n THE LEAD PLAINTIFF PROCESS<\/b>: The Private Securities Litigation Reform Act of 1995 permits any investor who purchased or acquired Rocket Pharmaceuticals securities during the Class Period to seek appointment as lead plaintiff in the Rocket Pharmaceuticals <\/i>class action lawsuit. A lead plaintiff is generally the\u00a0movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class. A lead plaintiff acts on behalf of all other class members in directing the\u00a0Rocket Pharmaceuticals <\/i>class action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the\u00a0Rocket Pharmaceuticals <\/i>class action lawsuit. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the\u00a0Rocket Pharmaceuticals <\/i>class action lawsuit.<\/p>\n

\n ABOUT ROBBINS GELLER<\/b>: Robbins Geller Rudman & Dowd LLP is one of the world’s leading law firms representing investors in securities fraud<\/span> and shareholder litigation. Our Firm has been ranked #1 in the\u00a0ISS Securities Class Action Services rankings for four out of the last five years for securing the most monetary relief for investors. In 2024, we recovered over $2.5 billion<\/span> for investors in securities-related class action cases \u2013 more than the next five law firms combined, according to\u00a0ISS. With 200 lawyers in 10 offices, Robbins\u00a0Geller is one of the largest plaintiffs’ firms in the world, and the Firm’s attorneys have obtained many of the largest securities class action recoveries in history, including the largest ever \u2013 $7.2 billion<\/span> \u2013 in In re Enron Corp. Sec. Litig.<\/i> Please visit the following page for more information:<\/p>\n

\n
\n https:\/\/www.rgrdlaw.com\/services-litigation-securities-fraud<\/span>.html<\/a>
\n <\/b>\n <\/p>\n

Past results do not guarantee future outcomes.
Services may be performed by attorneys in any of our offices.\u00a0<\/p>\n

Contact:<\/p>\n

Robbins\u00a0Geller Rudman & Dowd LLP
J.C. Sanchez, Jennifer N. Caringal<\/span>
655 W. Broadway, Suite 1900, San Diego, CA<\/span> 92101
800-449-4900
info@rgrdlaw.com<\/a><\/b><\/p>\n

\n \"Cision\" View original content to download multimedia:https:\/\/www.prnewswire.com\/news-releases\/rckt-investor-alert-rocket-pharmaceuticals-inc-investors-with-substantial-losses-have-opportunity-to-lead-the-rocket-pharmaceuticals-class-action-lawsuit-302480549.html<\/a><\/p>\n

SOURCE Robbins Geller Rudman & Dowd LLP<\/p>\n<\/p><\/div>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

PR Newswire SAN DIEGO , June 12, 2025 \/PRNewswire\/ —Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) securities between February 27, 2025 and May 26, 2025, inclusive (the “Class Period”), have until August 11, 2025 to seek appointment as lead plaintiff of the Rocket Pharmaceuticals class action lawsuit. Captioned\u00a0Ho v. Rocket Pharmaceuticals, Inc., No. 25-cv-10049 (D.N.J.), the Rocket Pharmaceuticals class action lawsuit charges Rocket Pharmaceuticals and one of Rocket Pharmaceuticals’ top executives with violations of the Securities Exchange Act of 1934. If you suffered substantial losses and wish to serve as lead plaintiff of the Rocket Pharmaceuticals class action lawsuit, please provide your information here: https:\/\/www.rgrdlaw.com\/cases-rocket-pharmaceuticals-inc-class-action-lawsuit-rckt.html You can also contact attorneys … <\/p>\n

Continue reading “RCKT INVESTOR ALERT: Rocket Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead the Rocket Pharmaceuticals Class Action Lawsuit”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-860263","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nRCKT INVESTOR ALERT: Rocket Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead the Rocket Pharmaceuticals Class Action Lawsuit - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/rckt-investor-alert-rocket-pharmaceuticals-inc-investors-with-substantial-losses-have-opportunity-to-lead-the-rocket-pharmaceuticals-class-action-lawsuit\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"RCKT INVESTOR ALERT: Rocket Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead the Rocket Pharmaceuticals Class Action Lawsuit - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire SAN DIEGO , June 12, 2025 \/PRNewswire\/ —Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) securities between February 27, 2025 and May 26, 2025, inclusive (the “Class Period”), have until August 11, 2025 to seek appointment as lead plaintiff of the Rocket Pharmaceuticals class action lawsuit. Captioned\u00a0Ho v. Rocket Pharmaceuticals, Inc., No. 25-cv-10049 (D.N.J.), the Rocket Pharmaceuticals class action lawsuit charges Rocket Pharmaceuticals and one of Rocket Pharmaceuticals’ top executives with violations of the Securities Exchange Act of 1934. If you suffered substantial losses and wish to serve as lead plaintiff of the Rocket Pharmaceuticals class action lawsuit, please provide your information here: https:\/\/www.rgrdlaw.com\/cases-rocket-pharmaceuticals-inc-class-action-lawsuit-rckt.html You can also contact attorneys … Continue reading "RCKT INVESTOR ALERT: Rocket Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead the Rocket Pharmaceuticals Class Action Lawsuit"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/rckt-investor-alert-rocket-pharmaceuticals-inc-investors-with-substantial-losses-have-opportunity-to-lead-the-rocket-pharmaceuticals-class-action-lawsuit\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-06-12T20:54:41+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/2542335\/robbins_geller_rudman_and_dowd_llp_logo_v2_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rckt-investor-alert-rocket-pharmaceuticals-inc-investors-with-substantial-losses-have-opportunity-to-lead-the-rocket-pharmaceuticals-class-action-lawsuit\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rckt-investor-alert-rocket-pharmaceuticals-inc-investors-with-substantial-losses-have-opportunity-to-lead-the-rocket-pharmaceuticals-class-action-lawsuit\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"RCKT INVESTOR ALERT: Rocket Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead the Rocket Pharmaceuticals Class Action Lawsuit\",\"datePublished\":\"2025-06-12T20:54:41+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rckt-investor-alert-rocket-pharmaceuticals-inc-investors-with-substantial-losses-have-opportunity-to-lead-the-rocket-pharmaceuticals-class-action-lawsuit\\\/\"},\"wordCount\":697,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rckt-investor-alert-rocket-pharmaceuticals-inc-investors-with-substantial-losses-have-opportunity-to-lead-the-rocket-pharmaceuticals-class-action-lawsuit\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/2542335\\\/robbins_geller_rudman_and_dowd_llp_logo_v2_Logo.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rckt-investor-alert-rocket-pharmaceuticals-inc-investors-with-substantial-losses-have-opportunity-to-lead-the-rocket-pharmaceuticals-class-action-lawsuit\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rckt-investor-alert-rocket-pharmaceuticals-inc-investors-with-substantial-losses-have-opportunity-to-lead-the-rocket-pharmaceuticals-class-action-lawsuit\\\/\",\"name\":\"RCKT INVESTOR ALERT: Rocket Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead the Rocket Pharmaceuticals Class Action Lawsuit - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rckt-investor-alert-rocket-pharmaceuticals-inc-investors-with-substantial-losses-have-opportunity-to-lead-the-rocket-pharmaceuticals-class-action-lawsuit\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rckt-investor-alert-rocket-pharmaceuticals-inc-investors-with-substantial-losses-have-opportunity-to-lead-the-rocket-pharmaceuticals-class-action-lawsuit\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/2542335\\\/robbins_geller_rudman_and_dowd_llp_logo_v2_Logo.jpg\",\"datePublished\":\"2025-06-12T20:54:41+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rckt-investor-alert-rocket-pharmaceuticals-inc-investors-with-substantial-losses-have-opportunity-to-lead-the-rocket-pharmaceuticals-class-action-lawsuit\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rckt-investor-alert-rocket-pharmaceuticals-inc-investors-with-substantial-losses-have-opportunity-to-lead-the-rocket-pharmaceuticals-class-action-lawsuit\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rckt-investor-alert-rocket-pharmaceuticals-inc-investors-with-substantial-losses-have-opportunity-to-lead-the-rocket-pharmaceuticals-class-action-lawsuit\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/2542335\\\/robbins_geller_rudman_and_dowd_llp_logo_v2_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/2542335\\\/robbins_geller_rudman_and_dowd_llp_logo_v2_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rckt-investor-alert-rocket-pharmaceuticals-inc-investors-with-substantial-losses-have-opportunity-to-lead-the-rocket-pharmaceuticals-class-action-lawsuit\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"RCKT INVESTOR ALERT: Rocket Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead the Rocket Pharmaceuticals Class Action Lawsuit\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"RCKT INVESTOR ALERT: Rocket Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead the Rocket Pharmaceuticals Class Action Lawsuit - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/rckt-investor-alert-rocket-pharmaceuticals-inc-investors-with-substantial-losses-have-opportunity-to-lead-the-rocket-pharmaceuticals-class-action-lawsuit\/","og_locale":"en_US","og_type":"article","og_title":"RCKT INVESTOR ALERT: Rocket Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead the Rocket Pharmaceuticals Class Action Lawsuit - Market Newsdesk","og_description":"PR Newswire SAN DIEGO , June 12, 2025 \/PRNewswire\/ —Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) securities between February 27, 2025 and May 26, 2025, inclusive (the “Class Period”), have until August 11, 2025 to seek appointment as lead plaintiff of the Rocket Pharmaceuticals class action lawsuit. Captioned\u00a0Ho v. Rocket Pharmaceuticals, Inc., No. 25-cv-10049 (D.N.J.), the Rocket Pharmaceuticals class action lawsuit charges Rocket Pharmaceuticals and one of Rocket Pharmaceuticals’ top executives with violations of the Securities Exchange Act of 1934. If you suffered substantial losses and wish to serve as lead plaintiff of the Rocket Pharmaceuticals class action lawsuit, please provide your information here: https:\/\/www.rgrdlaw.com\/cases-rocket-pharmaceuticals-inc-class-action-lawsuit-rckt.html You can also contact attorneys … Continue reading \"RCKT INVESTOR ALERT: Rocket Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead the Rocket Pharmaceuticals Class Action Lawsuit\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/rckt-investor-alert-rocket-pharmaceuticals-inc-investors-with-substantial-losses-have-opportunity-to-lead-the-rocket-pharmaceuticals-class-action-lawsuit\/","og_site_name":"Market Newsdesk","article_published_time":"2025-06-12T20:54:41+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/2542335\/robbins_geller_rudman_and_dowd_llp_logo_v2_Logo.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rckt-investor-alert-rocket-pharmaceuticals-inc-investors-with-substantial-losses-have-opportunity-to-lead-the-rocket-pharmaceuticals-class-action-lawsuit\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rckt-investor-alert-rocket-pharmaceuticals-inc-investors-with-substantial-losses-have-opportunity-to-lead-the-rocket-pharmaceuticals-class-action-lawsuit\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"RCKT INVESTOR ALERT: Rocket Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead the Rocket Pharmaceuticals Class Action Lawsuit","datePublished":"2025-06-12T20:54:41+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rckt-investor-alert-rocket-pharmaceuticals-inc-investors-with-substantial-losses-have-opportunity-to-lead-the-rocket-pharmaceuticals-class-action-lawsuit\/"},"wordCount":697,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rckt-investor-alert-rocket-pharmaceuticals-inc-investors-with-substantial-losses-have-opportunity-to-lead-the-rocket-pharmaceuticals-class-action-lawsuit\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/2542335\/robbins_geller_rudman_and_dowd_llp_logo_v2_Logo.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rckt-investor-alert-rocket-pharmaceuticals-inc-investors-with-substantial-losses-have-opportunity-to-lead-the-rocket-pharmaceuticals-class-action-lawsuit\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/rckt-investor-alert-rocket-pharmaceuticals-inc-investors-with-substantial-losses-have-opportunity-to-lead-the-rocket-pharmaceuticals-class-action-lawsuit\/","name":"RCKT INVESTOR ALERT: Rocket Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead the Rocket Pharmaceuticals Class Action Lawsuit - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rckt-investor-alert-rocket-pharmaceuticals-inc-investors-with-substantial-losses-have-opportunity-to-lead-the-rocket-pharmaceuticals-class-action-lawsuit\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rckt-investor-alert-rocket-pharmaceuticals-inc-investors-with-substantial-losses-have-opportunity-to-lead-the-rocket-pharmaceuticals-class-action-lawsuit\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/2542335\/robbins_geller_rudman_and_dowd_llp_logo_v2_Logo.jpg","datePublished":"2025-06-12T20:54:41+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rckt-investor-alert-rocket-pharmaceuticals-inc-investors-with-substantial-losses-have-opportunity-to-lead-the-rocket-pharmaceuticals-class-action-lawsuit\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/rckt-investor-alert-rocket-pharmaceuticals-inc-investors-with-substantial-losses-have-opportunity-to-lead-the-rocket-pharmaceuticals-class-action-lawsuit\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rckt-investor-alert-rocket-pharmaceuticals-inc-investors-with-substantial-losses-have-opportunity-to-lead-the-rocket-pharmaceuticals-class-action-lawsuit\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/2542335\/robbins_geller_rudman_and_dowd_llp_logo_v2_Logo.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/2542335\/robbins_geller_rudman_and_dowd_llp_logo_v2_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rckt-investor-alert-rocket-pharmaceuticals-inc-investors-with-substantial-losses-have-opportunity-to-lead-the-rocket-pharmaceuticals-class-action-lawsuit\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"RCKT INVESTOR ALERT: Rocket Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead the Rocket Pharmaceuticals Class Action Lawsuit"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/860263","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=860263"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/860263\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=860263"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=860263"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=860263"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}